Artios
7 known investors
Artios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043). The company operates a proprietary DDR drug-development platform called DcoDeR and advances a pipeline of oncology product candidates through clinical trials.
BiotechHealthtech
Investors Β· 7
Frequently asked questions
- What does Artios do?
- Artios develops DNA Damage Response (DDR)-based therapeutics for hard-to-treat solid tumors, including small-molecule inhibitors targeting ATR (alnodesertib) and DNA polymerase theta (ART6043). The company operates a proprietary DDR drug-development platform called DcoDeR and advances a pipeline of oncology product candidates through clinical trials.
- Who are Artios's investors?
- Artios's investors include Andera Partners, M Ventures, Novartis Venture Fund, Pfizer Venture Investments, RA Capital, Sofinnova Partners, SV Health Investors.